The Change of Systemic Immune-Inflammation Index Independently Predicts Survival of Colorectal Cancer Patients after Curative Resection
- PMID: 33293896
- PMCID: PMC7718069
- DOI: 10.1155/2020/4105809
The Change of Systemic Immune-Inflammation Index Independently Predicts Survival of Colorectal Cancer Patients after Curative Resection
Abstract
Background: The systemic immune-inflammation index (SII) has an important role in predicting survival in some solid tumors. However, little information is available concerning the change of the SII (∆SII) in colorectal cancer (CRC) after curative resection. This study was designed to evaluate the role of ∆SII in CRC patients who received surgery.
Methods: A total 206 patients were enrolled in this study. Clinicopathologic characteristics and survival were assessed. The relationships between overall survival (OS), disease-free survival (DFS), and ∆SII were analyzed with both univariate Kaplan-Meier and multivariate Cox regression methods.
Results: Based on the patient data, the receiver operating characteristic (ROC) optimal cutoff value of ∆SII was 127.7 for OS prediction. The 3-year and 5-year OS rates, respectively, were 60.4% and 36.7% in the high-∆SII group (>127.7) and 87.6% and 79.8% in the low-∆SII group (≤127.7). The 3-year and 5-year DFS rates, respectively, were 54.1% and 34.1% in the high-∆SII group and 80.3% and 78.5% in the low-∆SII group. In the univariate analysis, smoking, pathological stages III-IV, high-middle degree of differentiation, lymphatic invasion, vascular invasion, and the high-ΔSII group were associated with poor OS. Adjuvant therapy, pathological stages III-IV, vascular invasion, and ΔSII were able to predict DFS. Multivariate analysis revealed that pathological stages III-IV (HR = 0.442, 95% CI = 0.236-0.827, p = 0.011), vascular invasion (HR = 2.182, 95% CI = 1.243-3.829, p = 0.007), and the high-ΔSII group (HR = 4.301, 95% CI = 2.517-7.350, p < 0.001) were independent predictors for OS. Adjuvant therapy (HR = 0.415, 95% CI = 0.250-0.687, p = 0.001), vascular invasion (HR = 3.305, 95% CI = 1.944-5.620, p < 0.001), and the high-ΔSII group (HR = 4.924, 95% CI = 2.992-8.102, p < 0.001) were significant prognostic factors for DFS.
Conclusions: The present study demonstrated that ∆SII was associated with the clinical outcome in CRC patients undergoing curative resection, supporting the role of ∆SII as a prognostic biomarker.
Copyright © 2020 Qingqing Chen et al.
Conflict of interest statement
The authors declared that no conflicts of interest exist with respect to the authorship and/or publication of this article.
Figures



Similar articles
-
Prognostic value and clinicopathological significance of pre-and post-treatment systemic immune-inflammation index in colorectal cancer patients: a meta-analysis.World J Surg Oncol. 2025 Jan 13;23(1):11. doi: 10.1186/s12957-025-03662-z. World J Surg Oncol. 2025. PMID: 39806457 Free PMC article. Review.
-
Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.J Cell Mol Med. 2020 Mar;24(5):2993-3021. doi: 10.1111/jcmm.14934. Epub 2020 Jan 27. J Cell Mol Med. 2020. PMID: 31989747 Free PMC article.
-
Prognostic value of preoperative combined with postoperative systemic immune-inflammation index for disease-free survival after radical rectal cancer surgery: a retrospective cohort study.Transl Cancer Res. 2024 Jan 31;13(1):371-380. doi: 10.21037/tcr-23-1289. Epub 2024 Jan 8. Transl Cancer Res. 2024. PMID: 38410202 Free PMC article.
-
Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.Future Oncol. 2021 Jun;17(17):2141-2149. doi: 10.2217/fon-2020-1272. Epub 2021 Feb 26. Future Oncol. 2021. PMID: 33635094
-
Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis.Ann Med. 2021 Dec;53(1):1827-1838. doi: 10.1080/07853890.2021.1991591. Ann Med. 2021. PMID: 34647517 Free PMC article.
Cited by
-
Effect of the systemic immune-inflammation index on postoperative complications and the long-term prognosis of patients with colorectal cancer: a retrospective cohort study.J Gastrointest Oncol. 2022 Oct;13(5):2333-2339. doi: 10.21037/jgo-22-716. J Gastrointest Oncol. 2022. PMID: 36388661 Free PMC article.
-
Association between systemic Immune-inflammation index, systemic inflammation response index and adult osteoarthritis: national health and nutrition examination survey.BMC Musculoskelet Disord. 2025 May 29;26(1):529. doi: 10.1186/s12891-025-08792-9. BMC Musculoskelet Disord. 2025. PMID: 40442764 Free PMC article.
-
Prognostic value and clinicopathological significance of pre-and post-treatment systemic immune-inflammation index in colorectal cancer patients: a meta-analysis.World J Surg Oncol. 2025 Jan 13;23(1):11. doi: 10.1186/s12957-025-03662-z. World J Surg Oncol. 2025. PMID: 39806457 Free PMC article. Review.
-
Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection.Front Oncol. 2021 Sep 1;11:711206. doi: 10.3389/fonc.2021.711206. eCollection 2021. Front Oncol. 2021. PMID: 34540678 Free PMC article.
-
Support Tools in the Differential Diagnosis of Salivary Gland Tumors through Inflammatory Biomarkers and Radiomics Metrics: A Preliminary Study.Cancers (Basel). 2023 Mar 21;15(6):1876. doi: 10.3390/cancers15061876. Cancers (Basel). 2023. PMID: 36980760 Free PMC article.
References
-
- Bentzen S. M., Balslev I., Pedersen M., et al. Time to loco-regional recurrence after resection of Dukes' B and C colorectal cancer with or without adjuvant postoperative radiotherapy. A multivariate regression analysis. British Journal of Cancer. 1992;65(1):102–107. doi: 10.1038/bjc.1992.19. - DOI - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical